{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Editas Medicine, Inc."},"Symbol":{"label":"Symbol","value":"EDIT"},"Address":{"label":"Address","value":"11 HURLEY STREET, CAMBRIDGE, Massachusetts, 02141, United States"},"Phone":{"label":"Phone","value":"+1 617 401-9000"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company's only operating segment is developing and commercializing genome editing technology."},"CompanyUrl":{"label":"Company Url","value":"https://www.editasmedicine.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Gilmore Oâ€™Neill","title":"President, Chief Executive Officer & Director"},{"name":"Linda C. Burkly","title":"Chief Scientific Officer & Executive VP"},{"name":"Mei Baisong","title":"Chief Medical Officer & Senior Vice President"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}